Key Activities
Discovering new chemical entities derived from natural product scaffolds for the treatment of cluster headache and migraine with novel non-psychoactive molecules able to target psychedelic signalling pathways.
A NEW APPROACH
Key Activities in Drug Development for Cluster Headache and Migraine
- Discover and advance novel chemical entities for cluster headache and migraine.
- Select and validate targets with strong biological relevance to headache disorders.
- Design and optimise lead compounds for potency, selectivity, and developability.
- Build robust preclinical data packages to support candidate selection.
- Evaluate pharmacology and mechanism of action in relevant models.
- Characterise safety, tolerability, and early toxicology profiles.
- Optimise formulation, dosing, and delivery strategies for lead assets.
- Prepare IND-enabling studies to support clinical entry.
- Develop clear regulatory and clinical development plans for first-in-human studies.
- Progress the most promising candidates toward the clinic with a focus on meaningful patient impact.
